Ryan W. Holly

This paper introduces a novel targeted nanoparticle platform for cancer therapy, showing significant tumor reduction and complete ablation in preclinical models.

This paper introduces cataLYTACs, a new therapeutic modality that efficiently and durably degrades circulating proteins like IgE in vitro and in vivo, outperforming traditional inhibitors.

The paper develops a fluorescent probe to monitor lysosomal catabolism of internalized proteins and applies it to assess therapeutic LYTAC agents.